biotech stock news July 2026
FDA Panel Votes Down Capricor’s Deramiocel 9-3 for Duchenne Cardiomyopathy
Nine advisory committee members voted against Capricor’s Duchenne muscular dystrophy therapy on Tuesday. Three voted for it. The FDA’s own briefing document had called the primary evidence unconvincing before a single panelist spoke, and a nearly identical scene is playing out for a different company on the same regulatory stage today. Altimmune, meanwhile, needed no…
Tempus AI’s $1.5 Billion Personalis Deal and Celldex’s Phase 2 Miss This Week
BridgeBio’s rare disease drug cleared its first FDA hurdle on July 22. Celldex’s itch drug cleared every hurdle except the one that mattered, on July 21, one day earlier. One is a step closer to patients. The other proved its mechanism worked in a lab sense and got shelved anyway. In between, Tempus AI put…
